Andrew Polovin Sells 13,135 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 13,135 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $45.98, for a total value of $603,947.30. Following the completion of the transaction, the executive vice president now directly owns 154,171 shares in the company, valued at approximately $7,088,782.58. This represents a 7.85 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tempus AI Stock Performance

TEM opened at $48.03 on Thursday. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business has a 50 day simple moving average of $55.86 and a two-hundred day simple moving average of $51.48.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently made changes to their positions in TEM. Kovitz Investment Group Partners LLC bought a new stake in Tempus AI in the third quarter valued at $1,367,000. China Universal Asset Management Co. Ltd. bought a new position in Tempus AI in the 4th quarter worth $1,091,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Tempus AI in the 4th quarter worth about $178,000. Captrust Financial Advisors bought a new stake in shares of Tempus AI during the 3rd quarter valued at about $2,726,000. Finally, abrdn plc purchased a new position in shares of Tempus AI during the fourth quarter valued at about $2,784,000. Institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TEM. TD Cowen reiterated a “buy” rating and set a $74.00 price objective (up from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. William Blair reissued a “market perform” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Finally, Bank of America increased their target price on Tempus AI from $54.00 to $60.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.18.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.